BioDuro Opens State-of-the-Art Discovery Lab in Shanghai
News May 17, 2013
BioDuro announced it has opened a new state-of-the-art laboratory in Shanghai, strengthening its ability to provide biopharmaceutical clients an extensive range of customized drug discovery services in Asia Pacific. The new lab also enables the company to better support the business needs of its clients by increasing efficiency during discovery and development, and providing greater consistency among the stages of development. In addition, the location of the lab in the Waigaoqiao Free Trade Zone and its proximity to local and multinational pharmaceutical and biotechnology companies in Shanghai will foster their working relationships with BioDuro.
The 72,000-square-foot lab, accompanied by 20,000 square feet of office space, offers integrated drug metabolism and pharmacokinetic (DMPK), bioanalytical, chemistry, discovery biology and oncology pharmacology services. And, because BioDuro is part of the PPD organization, clients also are able to take advantage of a complete menu of clinical research services, as well as an extensive library of assays for testing.
“As a fully integrated life science research service provider, BioDuro has an experienced team of researchers and scientists with expertise in a wide range of drug discovery services,” said Jasmine Cui, Ph.D., general manager and chief scientific officer of BioDuro. “This new lab will allow us to meet the business needs of our clients more effectively by streamlining the discovery and development process, and continuing to enhance continuity and smooth transitions throughout the stages of development. For example, after a compound goes into Phase 0, the PPD organization can offer full clinical research services to develop the compound through post approval.”
BioDuro also has a state-of-the-art, 110,000-square-foot laboratory in Beijing. Through the two operations, BioDuro provides fully integrated, comprehensive drug discovery services covering development from target identification to preclinical/Phase 0.
Diabetic Ketoacidosis Assay Collaboration Between Ortho Clinical Diagnostics and EKF DiagnosticsNews
EKF’s Beta-Hydroxybutyrate LiquiColor® Assay for detection of predominant ketone body now available on Ortho’s VITROS® 4600 Chemistry System and VITROS® 5600 Integrated System.READ MORE
Key Cancer-Linked Proteins Thought to be ‘Undruggable’ Until NowNews
A new study published in Nature, conducted by an alliance between industry and academia involving the University of Liverpool, highlights a new approach to targeting key cancer-linked proteins, thought to be ‘undruggable’.READ MORE
Researchers Reveal How Superbug Secretes It’s ToxinNews
Monash University’s Biomedicine Discovery Institute (BDI) researchers have created the first high-resolution structure depicting a crucial part of the ‘superbug’ Pseudomonas aeruginosa. The image identifies the ‘nanomachine’ used by the highly virulent bacteria to secrete toxins, pointing the way for drug design targeting this.READ MORE